Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HER-2 amplification + RAS wild-type + BRAF wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HER-2 positive + HER-2 amplification (4)

RAS wild-type + HER-2 positive (4)

HER-2 amplification + KRAS G12D (3)

BRAF V600K + LDH elevation (3)

BRAF wild-type + HER-2 positive (2)

BRCA1 mutation + HER-2 negative (2)

BRCA2 mutation + HER-2 negative (2)

HER-2 S310F + HER-2 amplification (2)

HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)

HER-2 amplification + HER-2 L755S (2)

HER-2 amplification + PD-L1 expression (2)

HER-2 amplification + RAS wild-type (2)

HER-2 expression + HER-2 D769H (2)

HER-2 expression + HER-2 L869R (2)

HER-2 expression + HER-2 amplification (2)

HER-2 expression + TMB-H (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

TMB-H + HER-2 positive (2)

BRAF V600E + MSI-H (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

BRAF V600E + ROS1 fusion (2)

BRAF mutation + MET amplification (2)

BRAF mutation + MSI-L/dMMR (2)

BRAF mutation + TERT overexpression (2)

EZR overexpression + BRAF V600E (2)

IDH1 mutation + BRAF V600E (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

MSI-H/dMMR + BRAF V600E (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 overexpression + BRAF V600E (2)

AR positive + HER-2 amplification (1)

BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)

CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)

EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)

EGFR T790M + HER-2 amplification (1)

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)

ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)

ER positive + HER-2 D769H + HER-2 V777L (1)

ERBB2 G778A + CCNE1 amplification (1)

ERBB3 mutation + HER-2 amplification (1)

ERBB4 mutation + HER-2 positive (1)

HER-2 amplification + AXL expression (1)

HER-2 amplification + BRAF wild-type (1)

HER-2 amplification + CCNE1 expression (1)

HER-2 amplification + EGFR mutation (1)

HER-2 amplification + ER positive + PGR negative (1)

HER-2 amplification + HER-2 R157W (1)

HER-2 amplification + HER-2 mutation (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 elevation (1)

HER-2 elevation + TMB-H (1)

HER-2 elevation + TMB-L (1)

HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)

HER-2 mutation + HER-2 positive (1)

HER-2 mutation + TMB-H (1)

HER-2 overexpression + CCNE1 amplification (1)

HER-2 overexpression + HER-2 amplification (1)

HER-2 overexpression + KRAS G12C (1)

HER-2 overexpression + KRAS wild-type (1)

HER-2 overexpression + PTEN deletion (1)

HER-2 overexpression + RAS wild-type (1)

HER-2 positive + APC mutation (1)

HER-2 positive + GATA6 amplification (1)

HER-2 positive + MYC amplification (1)

HER-2 positive + TP53 mutation (1)

HER-2 underexpression + CCNE1 amplification (1)

HR positive + HER-2 amplification (1)

HR positive + HER-2 mutation (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS mutation + HER-2 positive (1)

MSI-H + HER-2 amplification (1)

MSI-H/dMMR + HER-2 mutation (1)

NF1 mutation + HER-2 positive (1)

PD-L1 overexpression + HER-2 exon 20 insertion (1)

PIK3C3 mutation + HER-2 positive (1)

PIK3CA H1047R + HER-2 amplification (1)

PIK3CA mutation + HER-2 amplification (1)

PIK3CA mutation + HER-2 positive (1)

PIK3CA mutation + HR positive + HER-2 negative (1)

PIK3R1 mutation + HER-2 positive (1)

POLE E790Q + ERBB2 amplification + TMB-H (1)

RAS wild-type + HER-2 amplification (1)

RAS wild-type + HER-2 overexpression (1)

STAT6 deletion + HER-2 overexpression (1)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF V600E + CDKN2A deletion + MYCN amplification (1)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600E + EGFR expression (1)

BRAF V600E + PTEN deletion (1)

BRAF V600E + SOX2 amplification (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRAF mutation + PD-L1 overexpression (1)

BRAF mutation + TMB-H (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

BRAF wild-type + HGF elevation (1)

CD8 elevation + BRAF V600 (1)

Chr t(11;14) + BRAF mutation (1)

EGFR exon 19 deletion + BRAF G464A (1)

EGFR overexpression + BRAF V600E (1)

EGFR overexpression + BRAF mutation (1)

HR positive + BRAF V600E (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIAA1549-BRAF fusion + PTEN deletion (1)

KRAS wild-type + BRAF V600E (1)

LDH elevation + BRAF mutation (1)

MAP2K1 mutation + BRAF wild-type (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

NRAS mutation + BRAF wild-type (1)

PD-L1 expression + BRAF negative (1)

PIK3CA mutation + BRAF wild-type (1)

SEMA6A overexpression + BRAF mutation (1)

SRC overexpression + BRAF V600E (1)

TNFAIP3 overexpression + BRAF mutation (1)

ER negative + HER-2 positive + PIK3CA H1047R (0)

ER positive + HER-2 negative + ER mutation (0)

HER-2 amplification + KRAS G12C (0)

HER-2 exon 20 mutation + HER-2 amplification (0)

HER-2 positive + FGFR1 amplification (0)

HR positive + HER-2 negative + TMB-L (0)

PIK3CA E453K + HER-2 positive (0)

PIK3CA E542K + HER-2 positive (0)

PIK3CA E542Q + HER-2 positive (0)

PIK3CA H1047L + HER-2 positive (0)

PIK3CA H1047R + HER-2 positive (0)

PIK3CA N345K + HER-2 positive (0)

PIK3CA amplification + HER-2 positive (0)

PD-L1 overexpression + BRAF mutation (0)

HER-2 positive + HER-2 amplification (4)

RAS wild-type + HER-2 positive (4)

HER-2 amplification + KRAS G12D (3)

BRAF V600K + LDH elevation (3)

BRAF wild-type + HER-2 positive (2)

BRCA1 mutation + HER-2 negative (2)

BRCA2 mutation + HER-2 negative (2)

HER-2 S310F + HER-2 amplification (2)

HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)

HER-2 amplification + HER-2 L755S (2)

HER-2 amplification + PD-L1 expression (2)

HER-2 amplification + RAS wild-type (2)

HER-2 expression + HER-2 D769H (2)

HER-2 expression + HER-2 L869R (2)

HER-2 expression + HER-2 amplification (2)

HER-2 expression + TMB-H (2)

RAS wild-type + BRAF wild-type + HER-2 positive (2)

TMB-H + HER-2 positive (2)

BRAF V600E + MSI-H (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PIK3CA mutation + SMAD4 mutation + MSI-H/dMMR (2)

BRAF V600E + ROS1 fusion (2)

BRAF mutation + MET amplification (2)

BRAF mutation + MSI-L/dMMR (2)

BRAF mutation + TERT overexpression (2)

EZR overexpression + BRAF V600E (2)

IDH1 mutation + BRAF V600E (2)

IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

IDH2 mutation + BRAF V600E (2)

IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (2)

MSI-H/dMMR + BRAF V600E (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 overexpression + BRAF V600E (2)

AR positive + HER-2 amplification (1)

BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)

CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)

EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)

EGFR T790M + HER-2 amplification (1)

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)

ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)

ER positive + HER-2 D769H + HER-2 V777L (1)

ERBB2 G778A + CCNE1 amplification (1)

ERBB3 mutation + HER-2 amplification (1)

ERBB4 mutation + HER-2 positive (1)

HER-2 amplification + AXL expression (1)

HER-2 amplification + BRAF wild-type (1)

HER-2 amplification + CCNE1 expression (1)

HER-2 amplification + EGFR mutation (1)

HER-2 amplification + ER positive + PGR negative (1)

HER-2 amplification + HER-2 R157W (1)

HER-2 amplification + HER-2 mutation (1)

HER-2 amplification + KRAS exon 2 wild-type (1)

HER-2 amplification + KRAS wild-type (1)

HER-2 elevation (1)

HER-2 elevation + TMB-H (1)

HER-2 elevation + TMB-L (1)

HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)

HER-2 mutation + HER-2 positive (1)

HER-2 mutation + TMB-H (1)

HER-2 overexpression + CCNE1 amplification (1)

HER-2 overexpression + HER-2 amplification (1)

HER-2 overexpression + KRAS G12C (1)

HER-2 overexpression + KRAS wild-type (1)

HER-2 overexpression + PTEN deletion (1)

HER-2 overexpression + RAS wild-type (1)

HER-2 positive + APC mutation (1)

HER-2 positive + GATA6 amplification (1)

HER-2 positive + MYC amplification (1)

HER-2 positive + TP53 mutation (1)

HER-2 underexpression + CCNE1 amplification (1)

HR positive + HER-2 amplification (1)

HR positive + HER-2 mutation (1)

KRAS G12D + HER-2 amplification + TMB-H (1)

KRAS mutation + HER-2 positive (1)

MSI-H + HER-2 amplification (1)

MSI-H/dMMR + HER-2 mutation (1)

NF1 mutation + HER-2 positive (1)

PD-L1 overexpression + HER-2 exon 20 insertion (1)

PIK3C3 mutation + HER-2 positive (1)

PIK3CA H1047R + HER-2 amplification (1)

PIK3CA mutation + HER-2 amplification (1)

PIK3CA mutation + HER-2 positive (1)

PIK3CA mutation + HR positive + HER-2 negative (1)

PIK3R1 mutation + HER-2 positive (1)

POLE E790Q + ERBB2 amplification + TMB-H (1)

RAS wild-type + HER-2 amplification (1)

RAS wild-type + HER-2 overexpression (1)

STAT6 deletion + HER-2 overexpression (1)

ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)

ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF V600E + CDKN2A deletion + MYCN amplification (1)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600E + EGFR expression (1)

BRAF V600E + PTEN deletion (1)

BRAF V600E + SOX2 amplification (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRAF mutation + PD-L1 overexpression (1)

BRAF mutation + TMB-H (1)

BRAF mutation + TMB-L + MSI-L/dMMR (1)

BRAF negative + GKAP1-NTRK2 exon 10-16 in-frame fusion (1)

BRAF wild-type + HGF elevation (1)

CD8 elevation + BRAF V600 (1)

Chr t(11;14) + BRAF mutation (1)

EGFR exon 19 deletion + BRAF G464A (1)

EGFR overexpression + BRAF V600E (1)

EGFR overexpression + BRAF mutation (1)

HR positive + BRAF V600E (1)

KIAA1549-BRAF fusion + MET amplification (1)

KIAA1549-BRAF fusion + PTEN deletion (1)

KRAS wild-type + BRAF V600E (1)

LDH elevation + BRAF mutation (1)

MAP2K1 mutation + BRAF wild-type (1)

MSI-H/dMMR + BRAF Mutation (1)

MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)

NRAS mutation + BRAF wild-type (1)

PD-L1 expression + BRAF negative (1)

PIK3CA mutation + BRAF wild-type (1)

SEMA6A overexpression + BRAF mutation (1)

SRC overexpression + BRAF V600E (1)

TNFAIP3 overexpression + BRAF mutation (1)

ER negative + HER-2 positive + PIK3CA H1047R (0)

ER positive + HER-2 negative + ER mutation (0)

HER-2 amplification + KRAS G12C (0)

HER-2 exon 20 mutation + HER-2 amplification (0)

HER-2 positive + FGFR1 amplification (0)

HR positive + HER-2 negative + TMB-L (0)

PIK3CA E453K + HER-2 positive (0)

PIK3CA E542K + HER-2 positive (0)

PIK3CA E542Q + HER-2 positive (0)

PIK3CA H1047L + HER-2 positive (0)

PIK3CA H1047R + HER-2 positive (0)

PIK3CA N345K + HER-2 positive (0)

PIK3CA amplification + HER-2 positive (0)

PD-L1 overexpression + BRAF mutation (0)

›

HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2	trastuzumab + lapatinib Sensitive: A2 - Guideline trastuzumab + lapatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2	trastuzumab + tucatinib Sensitive: A2 - Guideline trastuzumab + tucatinib Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colorectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colorectal Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: C3 – Early Trials pertuzumab + ado-trastuzumab emtansine Sensitive : C3	pertuzumab + ado-trastuzumab emtansine Sensitive: C3 – Early Trials pertuzumab + ado-trastuzumab emtansine Sensitive : C3